Nasopharyngeal cancer is a type of head and neck cancer that starts in the nasopharynx, which is the upper part of the throat behind the nose. It can be difficult to diagnose because it often does not cause any symptoms until it has reached an advanced stage. The global nasopharyngeal cancer drug market is expected to grow at a CAGR of 7.2% from 2021-2030.
The global nasopharyngeal cancer drug market can be segmented on the basis of type into BGB317, CB501, Apatinib, AP1387 and ARG110; on application into hospital and clinic; and on region into North America (NA), Latin America (LA), Europe (EU), Asia Pacific (APAC) and Middle East & Africa (MEA). In 2018, NA accounted for over 40% share in terms of revenue generated from sales across all regions globally due to high prevalence rates among adults aged 50 years or more as well as higher incidence rates among children aged 5-14 years old than other regions such as LA or EU.
- Increasing prevalence of nasopharyngeal cancer.
- Increasing awareness about the disease.
- Availability of new treatment options.
- Growing number of clinical trials.
- Rising disposable income.
Industry Growth Insights published a new data on “Nasopharyngeal Cancer Drug Market”. The research report is titled “Nasopharyngeal Cancer Drug Market research by Types (BGBA-317, CBT-501, Apatinib, APG-1387, ARGX-110, ATA-129, Others), By Applications (Hospital, Clinic, Others), By Players/Companies Ambrx Inc, arGEN-X BV, Atara Biotherapeutics Inc, AVEO Pharmaceuticals Inc, BeiGene Ltd, BioDiem Ltd, Biomics Biotechnologies Co Ltd, Bristol-Myers Squibb Company, CBT Pharmaceuticals Inc, Celgene Corp, Cell Medica Ltd, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Nasopharyngeal Cancer Drug Market Research Report
By Type
BGBA-317, CBT-501, Apatinib, APG-1387, ARGX-110, ATA-129, Others
By Application
Hospital, Clinic, Others
By Companies
Ambrx Inc, arGEN-X BV, Atara Biotherapeutics Inc, AVEO Pharmaceuticals Inc, BeiGene Ltd, BioDiem Ltd, Biomics Biotechnologies Co Ltd, Bristol-Myers Squibb Company, CBT Pharmaceuticals Inc, Celgene Corp, Cell Medica Ltd, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
232
Number of Tables & Figures
163
Customization Available
Yes, the report can be customized as per your need.
Global Nasopharyngeal Cancer Drug Market Report Segments:
The global Nasopharyngeal Cancer Drug market is segmented on the basis of:
Types
BGBA-317, CBT-501, Apatinib, APG-1387, ARGX-110, ATA-129, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Ambrx Inc
- arGEN-X BV
- Atara Biotherapeutics Inc
- AVEO Pharmaceuticals Inc
- BeiGene Ltd
- BioDiem Ltd
- Biomics Biotechnologies Co Ltd
- Bristol-Myers Squibb Company
- CBT Pharmaceuticals Inc
- Celgene Corp
- Cell Medica Ltd
- F. Hoffmann-La Roche Ltd
- GlaxoSmithKline Plc
Highlights of The Nasopharyngeal Cancer Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- BGBA-317
- CBT-501
- Apatinib
- APG-1387
- ARGX-110
- ATA-129
- Others
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Nasopharyngeal Cancer Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Nasopharyngeal cancer drug is a medication that is used to treat nasopharyngeal cancer.
Some of the major companies in the nasopharyngeal cancer drug market are Ambrx Inc, arGEN-X BV, Atara Biotherapeutics Inc, AVEO Pharmaceuticals Inc, BeiGene Ltd, BioDiem Ltd, Biomics Biotechnologies Co Ltd, Bristol-Myers Squibb Company, CBT Pharmaceuticals Inc, Celgene Corp, Cell Medica Ltd, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc.
The nasopharyngeal cancer drug market is expected to register a CAGR of 7.2%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Nasopharyngeal Cancer Drug Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Nasopharyngeal Cancer Drug Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Nasopharyngeal Cancer Drug Market - Supply Chain
4.5. Global Nasopharyngeal Cancer Drug Market Forecast
4.5.1. Nasopharyngeal Cancer Drug Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Nasopharyngeal Cancer Drug Market Size (000 Units) and Y-o-Y Growth
4.5.3. Nasopharyngeal Cancer Drug Market Absolute $ Opportunity
5. Global Nasopharyngeal Cancer Drug Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Nasopharyngeal Cancer Drug Market Size and Volume Forecast by Type
5.3.1. BGBA-317
5.3.2. CBT-501
5.3.3. Apatinib
5.3.4. APG-1387
5.3.5. ARGX-110
5.3.6. ATA-129
5.3.7. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Nasopharyngeal Cancer Drug Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Nasopharyngeal Cancer Drug Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Clinic
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Nasopharyngeal Cancer Drug Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Nasopharyngeal Cancer Drug Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Nasopharyngeal Cancer Drug Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Nasopharyngeal Cancer Drug Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Nasopharyngeal Cancer Drug Demand Share Forecast, 2019-2026
9. North America Nasopharyngeal Cancer Drug Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Nasopharyngeal Cancer Drug Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Nasopharyngeal Cancer Drug Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Clinic
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Nasopharyngeal Cancer Drug Market Size and Volume Forecast by Type
9.7.1. BGBA-317
9.7.2. CBT-501
9.7.3. Apatinib
9.7.4. APG-1387
9.7.5. ARGX-110
9.7.6. ATA-129
9.7.7. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Nasopharyngeal Cancer Drug Demand Share Forecast, 2019-2026
10. Latin America Nasopharyngeal Cancer Drug Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Nasopharyngeal Cancer Drug Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Nasopharyngeal Cancer Drug Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Clinic
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Nasopharyngeal Cancer Drug Market Size and Volume Forecast by Type
10.7.1. BGBA-317
10.7.2. CBT-501
10.7.3. Apatinib
10.7.4. APG-1387
10.7.5. ARGX-110
10.7.6. ATA-129
10.7.7. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Nasopharyngeal Cancer Drug Demand Share Forecast, 2019-2026
11. Europe Nasopharyngeal Cancer Drug Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Nasopharyngeal Cancer Drug Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Nasopharyngeal Cancer Drug Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Clinic
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Nasopharyngeal Cancer Drug Market Size and Volume Forecast by Type
11.7.1. BGBA-317
11.7.2. CBT-501
11.7.3. Apatinib
11.7.4. APG-1387
11.7.5. ARGX-110
11.7.6. ATA-129
11.7.7. Others
11.8. Basis Point hare (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Nasopharyngeal Cancer Drug Demand Share, 2019-2026
12. Asia Pacific Nasopharyngeal Cancer Drug Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Nasopharyngeal Cancer Drug Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Nasopharyngeal Cancer Drug Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Clinic
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Nasopharyngeal Cancer Drug Market Size and Volume Forecast by Type
12.7.1. BGBA-317
12.7.2. CBT-501
12.7.3. Apatinib
12.7.4. APG-1387
12.7.5. ARGX-110
12.7.6. ATA-129
12.7.7. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Nasopharyngeal Cancer Drug Demand Share, 2019-2026
13. Middle East & Africa Nasopharyngeal Cancer Drug Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Nasopharyngeal Cancer Drug Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Nasopharyngeal Cancer Drug Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Clinic
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Nasopharyngeal Cancer Drug Market Size and Volume Forecast by Type
13.7.1. BGBA-317
13.7.2. CBT-501
13.7.3. Apatinib
13.7.4. APG-1387
13.7.5. ARGX-110
13.7.6. ATA-129
13.7.7. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Nasopharyngeal Cancer Drug Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Nasopharyngeal Cancer Drug Market: Market Share Analysis
14.2. Nasopharyngeal Cancer Drug Distributors and Customers
14.3. Nasopharyngeal Cancer Drug Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Ambrx Inc
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. arGEN-X BV
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Atara Biotherapeutics Inc
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. AVEO Pharmaceuticals Inc
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. BeiGene Ltd
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. BioDiem Ltd
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Biomics Biotechnologies Co Ltd
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Bristol-Myers Squibb Company
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. CBT Pharmaceuticals Inc
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Celgene Corp
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Cell Medica Ltd
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. F. Hoffmann-La Roche Ltd
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. GlaxoSmithKline Plc
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
